Longboard Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview

Longboard Pharmaceuticals

30/07/2024 15:16

* Longboard Pharmaceuticals Inc  LBPH.OQ   LBPH.O  is
expected
to show no change in quarterly revenue when it reports 
results on August 1 for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Longboard
Pharmaceuticals Inc
is for a loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Longboard
Pharmaceuticals Inc is $45.00​, above​ its last closing price
of $34.88. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.49       -0.49      -0.42     Beat    13.6
 Jan. 1 0001   -0.60       -0.60      -0.62     Missed  -3.8
 Sep. 30 2023              -0.70      -0.55     Beat    21.9​
 Jun. 30 2023  -0.58       -0.60      -0.65     Missed  -9.1
 ​​Jan.        -0.57       -0.57      -0.66     Missed  
 1 0001                                                 
 Dec. 31 2022  -0.70       -0.69      -0.66     Beat    5​
 Jan. 1 0001   -0.66       -0.64      -0.68     Missed  -6.9
 Jun. 30 2022  -0.60       -0.57      -0.67     Missed  -17
 This summary was machine generated July 30 at 14:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)